Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis

Hou,Liqiong; Zhao,Tieyun; Liu,Yunhui; Zhang,Yiyi

doi:10.3892/etm.2015.2277

Efficacy and safety of sitagliptin compared with sulfonylurea therapy in patients with type 2 diabetes showing inadequately controlled glycosylated hemoglobin with metformin monotherapy: A meta-analysis

Authors:
- Liqiong Hou
- Tieyun Zhao
- Yunhui Liu
- Yiyi Zhang
View Affiliations

Affiliations: Department of Endocrinology and Metabolism, West China Hospital of Sichuan University, Chengdu, Sichuan 610000, P.R. China
Published online on: February 9, 2015 https://doi.org/10.3892/etm.2015.2277
Pages: 1528-1536

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous randomized controlled trials (RCTs) have reported conflicting results for the efficacy of sitagliptin and sulfonylurea therapy in patients with type 2 diabetes mellitus showing inadequate glycemic control with metformin monotherapy. To clarify these findings, a meta‑analysis was conducted of the outcomes of all published RCTs comparing sitagliptin with sulfonylureas in the treatment of type 2 diabetes mellitus. Standard medical databases were searched to identify relevant English‑ and Chinese‑language RCTs. RCT results were compared regarding the mean change in glycated hemoglobin (HbA1c) level; the proportion achieving <7% HbAlc; and a change in body weight. No significant differences were found between the metformin plus sitagliptin and metformin plus sulfonylurea groups regarding HbAlc or the proportion achieving <7% HbAlc, while the metformin plus sitagliptin group experienced fewer hypoglycemic events (P<0.00001) and a greater reduction in body weight (P<0.00001). Metformin plus sitagliptin therapy may decrease HbAlc values in patients with type 2 diabetes mellitus who are not achieving their glycemic targets with metformin monotherapy in a manner similar to metformin plus sulfonylurea therapy, whilst posing a lower risk of hypoglycemia, and yielding a more beneficial effect on body weight.

View Figures

View References

1	Stulc T and Sedo A: Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract. 88:125–131. 2010. View Article : Google Scholar : PubMed/NCBI
2	Choudhury SR, Datta A, Chanda S, et al: Overview of current and upcoming strategies implied for the therapy of type 2 diabetes mellitus. Curr Diabetes Rev. 10:275–282. 2014. View Article : Google Scholar : PubMed/NCBI
3	Eurich DT, McAlister FA, Blackburn DF, et al: Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ. 335:4972007. View Article : Google Scholar : PubMed/NCBI
4	Saenz A, Fernandez-Esteban I, Mataix A, et al: Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 3:CD0029662005.PubMed/NCBI
5	IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med. 23:579–593. 2006. View Article : Google Scholar : PubMed/NCBI
6	National Collaborating Centre for Chronic Conditions (UK). Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). National Institute for Health and Clinical Excellence: Guidance. Royal College of Physicians; London: 2008
7	American Diabetes Association. Standards of medical care in diabetes - 2009. Diabetes Care. 32(Suppl 1): S13–S61. 2009. View Article : Google Scholar
8	American Diabetes Association. Standards of medical care in diabetes - 2010. Diabetes Care. 33(Suppl 1): S11–S61. 2010. View Article : Google Scholar
9	Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association and the European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 32:193–203. 2009. View Article : Google Scholar :
10	Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 287:360–372. 2002. View Article : Google Scholar : PubMed/NCBI
11	Goldstein BJ, Feinglos MN, Lunceford JK, et al; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 30:1979–1987. 2007. View Article : Google Scholar : PubMed/NCBI
12	Charbonnel B, Karasik A, Liu J, et al; Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 29:2638–2643. 2006. View Article : Google Scholar : PubMed/NCBI
13	Williams-Herman D, Johnson J, Teng R, et al: Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin. 25:569–583. 2009. View Article : Google Scholar : PubMed/NCBI
14	Arechavaleta R, Seck T, Chen Y, et al: Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 13:160–168. 2011. View Article : Google Scholar : PubMed/NCBI
15	Koren S, Shemesh-Bar L, Tirosh A, et al: The effect of sitagliptin versus glibenclamide on arterial stiffness, blood pressure, lipids, and inflammation in type 2 diabetes mellitus patients. Diabetes Technol Ther. 14:561–567. 2012. View Article : Google Scholar : PubMed/NCBI
16	Nauck MA, Meininger G, Sheng D, et al; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 9:194–205. 2007. View Article : Google Scholar : PubMed/NCBI
17	Seck T, Nauck M, Sheng D, et al; Sitagliptin Study 024 Group. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract. 64:562–576. 2010. View Article : Google Scholar : PubMed/NCBI
18	Srivastava S, Saxena GN, Keshwani P and Gupta R: Comparing the efficacy and safety profile of sitagliptin versus glimepiride in patients of type 2 diabetes mellitus inadequately controlled with metformin alone. J Assoc Physicians India. 60:27–30. 2012.PubMed/NCBI
19	Li WH, Lin M and Zhang XJ: Comparison on adding sitagliptin or glimepiride in poorly controlled overweight type 2 diabetes with oral metformin. Zhongguo Yi Yuan Yao Xue Za Zhi. 32:792–794. 2012.(In Chinese).
20	Higgins JPT and Altman DG: Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions. Higgins JPT and Green S: John Wilry & Sons; Chichester: pp. 187–241. 2008, View Article : Google Scholar
21	DeFronzo RA: Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 131:281–303. 1999. View Article : Google Scholar : PubMed/NCBI
22	Inzucchi SE: Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA. 287:360–372. 2002. View Article : Google Scholar : PubMed/NCBI
23	Bergman AJ, Stevens C, Zhou Y, et al: Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther. 28:55–72. 2006. View Article : Google Scholar : PubMed/NCBI
24	Herman GA, Stevens C, Van Dyck K, et al: Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther. 78:675–688. 2005. View Article : Google Scholar : PubMed/NCBI
25	Maedler K, Carr RD, Bosco D, et al: Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 90:501–506. 2005. View Article : Google Scholar
26	Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 26:2929–2940. 2003. View Article : Google Scholar : PubMed/NCBI
27	Krentz AJ and Bailey CJ: Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 65:385–411. 2005. View Article : Google Scholar : PubMed/NCBI